Repligen AIDS vaccine

Executive Summary

Company begins Phase I trial with a potential HIV therapeutic vaccine, RP400c immunogen, at the University of Colorado Health Sciences Center, Repligen announces June 7. The RP400c candidate vaccine contains the HIV V3 loop segment, which is the primary target for antibodies that neutralize the virus. Repligen says it has modified its ongoing agreement with Merck for the development of a prophylactic HIV vaccine to allow Repligen to conduct independently the initial studies of RP400c. After that, Merck has the option to compensate Repligen for development costs and become a codeveloper and copromoter of the vaccine candidate.